ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep
New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships
7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.
18% of couples reported sleeping in separate rooms due to snoring and restlessness.
Women report fewer quality sleep nights and more difficulties falling asleep than men.
SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), a global health technology leader focused on sleep, breathing, and care delivered in the home, today unveiled the findings of its fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscores a widespread global sleep crisis, with people losing an average of nearly three nights of restorative sleep each week.
Despite a trend towards growing awareness of sleep's importance, many continue to suffer in silence and remain trapped in a cycle of exhaustion. The research reveals that nearly one in four (22%) respondents choose to just live with poor sleep rather than seek help. With poor sleep found to impact our lives, from work1, to relationships2, and mental health, there is an urgent need for increased awareness and action on sleep health.
A World Without Rest
About one-third of survey respondents report difficulty falling or staying asleep three or more times per week, citing stress (57%), anxiety (46%), and financial pressures (31%) as primary disruptors. While well-rested individuals experience improved mood, concentration, and productivity, those struggling with poor sleep report excessive daytime sleepiness, irritability, and difficulty concentrating. Yet few take proactive steps to improve their sleep health:
89% of respondents believe sleep makes them feel better about themselves, but only 24% would take immediate action to address sleep issues.
22% globally, and up to 41% in Australia, chose to 'just live with' poor sleep.
45% do not track their sleep, missing valuable insights that could improve sleep quality.
'Sleep is as vital to health as diet and exercise, yet millions struggle in silence,' said Carlos M. Nunez, M.D., ResMed's Chief Medical Officer. 'This research highlights an urgent gap in awareness and action—one that needs immediate attention, to improve global health outcomes.'
Poor Sleep: The Hidden Drain on Workplace Productivity
Quality sleep directly impacts workplace performance, but many employees struggle due to sleep deprivation:
A staggering 71% of employed respondents globally have called in sick due to poor sleep at least once in their career, with the highest rates in India (94%), followed by China (78%), Singapore (73%), and the U.S. (70%).
Nearly half (47%) of the workforce surveyed feel that their sleep health isn't a priority for their employers, presenting an opportunity for employer initiatives to encourage healthy sleep habits.
Bedtime Blues: Sleep Impacts Relationships
Responses from the survey suggest that sleep may play an important role in the health of our relationships:
18% of couples permanently opt for a 'sleep divorce,' choosing to sleep apart due to snoring and restlessness.
Among those who sleep separately, 31% reported improved relationships, while 30% feel theirs have worsened.
Sleep separation also impacts intimacy — 28% say their sex life has improved, while 22% report the opposite.
Sleep Quality Isn't Equal Across Genders
Women experience poorer sleep quality than men:
Women report fewer nights of quality sleep than men (3.83 nights vs. 4.13 nights) per week.
38% of women struggle to fall asleep compared to 29% of men.
Hormonal changes—particularly menopause—are a significant but often overlooked factor affecting sleep, with 44% of menopausal women reporting difficulty falling asleep at least three times per week, compared to 33% of non-menopausal women.
Take Action on Sleep Health
'Chronic poor sleep impacts our relationships, workplace productivity, and increases the risk of cognitive decline, mood disorders, and serious health conditions like heart failure and stroke,' added Dr. Nunez. 'For individuals with untreated or poorly managed sleep apnea, these risks are even greater. That's why talking with a doctor about treating disrupted sleep is important.'
Are you getting enough sleep? Read the full 2025 Global Sleep Survey to learn more about the trends impacting the way we sleep. To assess your sleep health, take our sleep assessment.
Survey MethodologyResMed commissioned a survey of 30,026 individuals in the United States (5,000), China (5,000), India (5,000), United Kingdom (2,000), Germany (2,004), France (2,001), Australia (1,501), Japan (1,500), Korea (1,500), Thailand (1,519), New Zealand (1,000), Singapore (1,000), and Hong Kong (1,001). The samples within each country were representative of the population's gender and age breakdowns. The survey was fielded by PureSpectrum from 12 to 28 December 2024.
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
Contacts
For media628-278-6471news@resmed.com
For investors+1 858.836.5000investorrelations@resmed.com
1 Routinely assessing patients' sleep health is time well spent, Jean-Philippe Chaput, Judy Shiau, Preventive Medicine Reports Volume 14, June 2019, 1008512 Gordon AM, Chen S. The role of sleep in interpersonal conflict: Do sleepless nights mean worse fights? Social Psychological and Personality Science. 2014;5(2):168–175

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
$4.93 Bn Collagen Supplements Markets, 2030 - Global Trends, Opportunities, and Forecasts: Aging Population and Fitness Trends Drive Expansion, Gummies and Powders Boost Adoption
Key market opportunities include tapping into the rising health consciousness and demand for preventive health products, particularly among aging and fitness-focused consumers. Offering diverse product forms and leveraging endorsements can enhance market penetration. Growth in plant-based collagen alternatives also presents new avenues. Collagen Supplements Market Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Collagen Supplements Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to Collagen Supplements Market was valued at USD 3.13 Billion in 2024 and is expected to reach USD 4.93 Billion by 2030, rising at a CAGR of 7.82% Market growth is being propelled by increasing consumer awareness regarding the health and beauty benefits of collagen, which plays a key role in maintaining skin elasticity, joint mobility, and connective tissue strength. Demand is particularly strong among aging populations, fitness-conscious consumers, and individuals focused on preventive health. The versatility of product forms, including powders, capsules, and gummies, has enhanced consumer accessibility and convenience, driving broader market adoption. Endorsements by public figures and strategic innovations by manufacturers are further boosting interest and demand. With wellness trends gaining traction worldwide, collagen supplements have established a firm position in the broader functional health product landscape. Increasing Health Consciousness Heightened health awareness is fueling consumer interest in wellness-enhancing products, positioning collagen supplements as a preferred choice for holistic health management. As people shift from reactive to proactive health approaches, collagen has gained recognition for its role in supporting skin vitality, bone strength, and joint flexibility. The association of collagen with external beauty indicators such as radiant skin, healthy nails, and strong hair also contributes to its rising popularity. Consumers are increasingly seeking multi-functional supplements that align with their goals for longevity and aesthetic well-being. Furthermore, global demographic shifts-especially the rise in aging populations-are intensifying demand for collagen-based solutions that support healthy aging and mobility, reinforcing the supplement's value in modern wellness routines. Regulatory Complexity The collagen supplements market faces significant regulatory challenges due to inconsistent global classification and compliance requirements. Countries differ in how they categorize collagen products-as foods, nutraceuticals, or pharmaceuticals-resulting in varied regulations for safety, labeling, and marketing claims. These inconsistencies create obstacles for international product launches and raise operational costs due to the need for localized compliance strategies. Regulatory authorities also place high emphasis on verifying the safety and ethical sourcing of collagen ingredients, particularly those derived from bovine, marine, or porcine origins. This requires companies to adopt rigorous quality control and traceability systems, adding complexity and cost to manufacturing and supply chain operations. The absence of standardized global guidelines further limits scalability and creates market entry barriers for new players. Key Market Trends: Plant-Based Collagen Alternatives The rise of plant-based collagen alternatives is shaping the future of the collagen supplements market, responding to growing demand for vegan, ethical, and sustainable wellness products. Traditional animal-derived collagen is increasingly being supplemented or replaced by formulations that stimulate the body's own collagen production using plant-based compounds. These alternatives often include nutrients like vitamin C, zinc, silica, and amino acids sourced from botanicals. In parallel, advancements in biotechnology are enabling the production of lab-engineered, bio-identical collagen through fermentation techniques using yeast or bacteria-offering a cruelty-free, environmentally friendly option. These innovations cater to a diverse consumer base, including vegetarians, vegans, and those with dietary restrictions, thereby expanding the market's reach. Key Attributes: Report Attribute Details No. of Pages 186 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $3.13 Billion Forecasted Market Value (USD) by 2030 $4.93 Billion Compound Annual Growth Rate 7.8% Regions Covered Global Report Scope Competitive Landscape Optimum Nutrition Inc BioTechUSA TCI Co Ltd Further Food Vital Proteins LLC Hunter and Gather Foods Shiseido Co Ltd. Clorox Co/The Bountiful Co/The Codeage LLC Collagen Supplements Market, By Form: Pills & Gummies Powder Liquid/Drinks Collagen Supplements Market, By Distribution Channel: Pharmacy Online Store Specialty Store Collagen Supplements Market, By Region: North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Asia-Pacific China Japan India Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE Kuwait For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Collagen Supplements Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Super-high-yield stocks often deliver heaps of passive income early on, but they aren't famous for rapid payout raises. Pfizer offers a sky-high yield, but its payout has been rising slowly. Prologis offers a decent yield, and it's been raising its payout at an exciting pace. 10 stocks we like better than Prologis › Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Should you chase high yields from slow-growing businesses or invest in lower-yield providers with more predictable cash flows? Lately, Pfizer (NYSE: PFE) and Prologis (NYSE: PLD) have been perfect examples of the trade-off between attractive yields and dividend growth. Pfizer offers a sky-high yield that's climbing slowly. Prologis offers a much lower yield, but it's been raising its payout at a remarkable pace. Here's a closer look at both to help you decide which one fits your goals. Shares of Pfizer have fallen about 62% from their COVID-19 pandemic highs. The stock is way down, but the company has raised its payout every year since 2009. At its beaten-down price, this stock offers an eye-popping 7.3% dividend yield. Pfizer's COVID-19 vaccine, Comirnaty, and antiviral treatment, Paxlovid, drove adjusted earnings up to $6.58 per share in 2022. Sinking demand for COVID-19 vaccines and treatments reduced adjusted earnings to just $3.11 per share last year. In 2025, Pfizer expects a significant earnings contraction. At the midpoint of the guided range management provided this April, adjusted earnings are expected to fall by 6.8% this year. The $2.80 per share management expects at the low end of the guided range is more than enough to support a dividend payout currently set at an annualized $1.72 annually, but there could be further contractions ahead. Eliquis is a next-generation blood thinner that Pfizer markets in collaboration with Bristol Myers Squibb. It's currently responsible for 14% of Pfizer's total revenue and is likely to lose ground to generic competition in the lucrative U.S. market in 2028. Long before Eliquis loses ground to generic competition, the company's lead growth driver, Vyndaquel, could stumble. BridgeBio launched a competing treatment called Attruby in late 2024, and it's been exceeding expectations. Pfizer's facing patent cliffs, but it also has one of the most productive development pipelines in the industry. Last year alone, the Food and Drug Administration issued more than a dozen approvals to new Pfizer treatments and several that are already on the market. With plenty of new products to market, the drugmaker has a good chance to continue its payout-raising streak in the decade ahead. As more folks do their shopping online, demand for warehouses that can support e-commerce has soared. By anticipating the demand, Prologis has become the world's largest real estate investment trust (REIT) that everyday investors can buy shares of. Fear and uncertainty regarding the taxes businesses need to pay when importing goods to the U.S. have pressured the stock. It's down about 12% from a peak it set in March. At its beaten-down price, it offers a 3.7% yield. Prologis has been able to raise its dividend by 11.7% annually over the past five years. At this pace, investors who buy at recent prices could begin receiving a double-digit yield on cost in less than a decade. Amazon, Home Depot, and FedEx are Prologis' largest customers. These three tenants are responsible for only 8.2% of the rent payments Proligis receives every month. This high level of diversification is a big reason it can boast industry-leading credit ratings. With an A2 rating from Moody's and an A rating from S&P Global, the weighted average interest rate on Prologis' outstanding debts was just 3.1% at the end of March. Acquiring and developing properties is an important part of this REIT's business, but it also acts as a lender. With an enviable credit rating, it can produce a strong profit while offering rates that its smaller competitors can't match. For companies that own their warehouses, selling them to Prologis and leasing them back is often their lowest-cost source of capital. With the vast majority of the world's logistics real estate still owned by the companies that use it, Prologis could continue growing at a rapid pace for decades to come. Pfizer offers a yield that's almost twice as high as Prologis's, but the pharmaceutical giant has been raising its payout at less than half the pace of the logistics REIT. Pfizer might be a good option for folks near retirement age. For income-seeking investors, though, Prologis seems like the better dividend stock to buy now. Before you buy stock in Prologis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Prologis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Cory Renauer has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Bristol Myers Squibb, FedEx, Home Depot, Moody's, Pfizer, Prologis, and S&P Global. The Motley Fool recommends BridgeBio Pharma and recommends the following options: long January 2026 $90 calls on Prologis. The Motley Fool has a disclosure policy. Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
ASEAN Point of Care (POC) Diagnostics Market Report 2025-2030
Vietnam emerges as the fastest-growing market, bolstered by strong primary healthcare enhancements. The infectious disease testing segment is set to witness the highest growth, driven by advanced molecular and immunoassay technologies. ASEAN Point of Care Diagnostics Market Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "ASEAN Point of Care Diagnostics Market by Product (Infectious Disease (TB, Hepatitis, STDs, HAIs), Glucose, Cardiometabolic, Pregnancy, Coagulation), Technology (Lateral Flow Assays, Biochemistry, MDx), End User (Home Care, Hospitals) - Forecast to 2030" has been added to offering. The ASEAN point of care diagnostics market is projected to expand from USD 1.08 billion in 2025 to USD 1.36 billion by 2030, recording a CAGR of 4.7% over the forecast period. This growth is predominantly driven by favorable government policies and increased funding investments that bolster the demand for Point of Care (POC) testing across the ASEAN region. Governments in ASEAN countries are increasingly adopting POC technologies to enhance health access, reduce costs, and improve patient outcomes. Initiatives including strategic partnerships, research, and nationwide screening campaigns further promote POC usage, offering significant growth opportunities for diagnostic firms. In numerous developing regions where health infrastructure remains underdeveloped, POC devices facilitate the decentralization of diagnostics, thereby broadening access to essential testing. This report categorizes the market by product, technology, end user, and country. It comprehensively covers key growth drivers, restraints, opportunities, and challenges, providing insights into industry players, strategies, and recent developments. A competitive analysis of emerging ASEAN point-of-care diagnostics startups is also included. Key market players include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Sysmex Corporation, and Danaher Corporation, among others. The report provides insights into the following points: Analysis of factors influencing market growth including the rise of infectious and chronic diseases, government initiatives, and public-private partnerships. Product Development/Innovation: Detailed insights into upcoming technologies and new product launches in the ASEAN market. Market Development: Comprehensive information on lucrative markets across ASEAN countries. Market Diversification: Insights into new products, untapped geographies, and investments. Competitive Assessment: In-depth analysis of leading players' market shares, strategies, and offerings. Infectious disease testing products anticipated to register the highest growth rate This market segment encompasses infectious disease testing products, glucose monitoring products, cardiometabolic testing products, among others. The infectious disease testing products segment's rapid growth is driven by ASEAN efforts to enhance disease surveillance. The frequency of infectious disease outbreaks and the need for rapid diagnosis, particularly in rural and urban healthcare settings, underpin this demand. Advances in molecular platforms and immunoassays further foster the sector's expansion. By technology, the Biochemistry segment accounted for the largest market share in 2024 The market is segmented into lateral flow assays, rapid tests, and biochemistry. Biochemistry held the largest share, attributed to its broad applicability in various essential tests such as glucose and electrolyte analysis. The high incidence of chronic diseases in ASEAN countries necessitates these diagnostics, with biochemistry testing's ease of use and cost-effectiveness making it ideal for decentralized healthcare environments. The demand for early disease detection further supports biochemistry's leading position in the market. Vietnam is the fastest-growing market for point of care diagnostics in the ASEAN region Within ASEAN, Vietnam is poised for the highest growth, largely due to its initiatives post-COVID-19 to strengthen primary healthcare and nationwide screening. Vietnam's commitment to enhancing healthcare infrastructure, particularly in infectious disease management, is evident in its robust surveillance systems. Their performance in global health security indicators emphasizes their capability to adopt POC diagnostics effectively. Key Attributes Report Attribute Details No. of Pages 334 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $1.08 Billion Forecasted Market Value (USD) by 2030 $1.36 Billion Compound Annual Growth Rate 4.7% Regions Covered Asia-Pacific Key Topics CoveredMarket Dynamics Drivers Rising Incidence of Infectious Diseases Increasing Prevalence of Chronic Diseases Favorable Government Initiatives for POC Testing Rising Number of Public-Private Partnerships (PPPs) Challenges Pricing Pressure on Manufacturers Stringent Regulatory Approval Process for Product Commercialization Opportunities Gradual Shift Toward Decentralized Healthcare Systems Availability of POC Tests with Multiplexing Capabilities Industry Trends Trends/Disruptions Impacting Customers' Businesses Companies Profiled in the ASEAN POC Market Abbott F. Hoffmann-La Roche Ltd. Siemens Healthineers AG Sysmex Corporation Danaher Corporation BD Quidelortho Corporation Cardinal Health bioMerieux EKF Diagnostics Holdings PLC Thermo Fisher Scientific Inc. Accubiotech, Co. Ltd. Biosynex SA SD Biosensor, Inc. Sekisui Diagnostics Werfen Trinity Biotech PTS Diagnostics Lifescan IP Holdings, LLC CTK Biotech, Inc. Wondfo Arkray, Inc. Xiamen Boson Biotech Co. Ltd. Credo Diagnostics Biomedical Pte. Ltd. Anbio Biotechnology Inc. SG Diagnostics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment ASEAN Point of Care Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data